Kynurenic acid

Catalog No.S4719 Batch:S471904

Print

Technical Data

Formula

C10H7NO3
Molecular Weight 189.17 CAS No. 492-27-3
Solubility (25°C)* In vitro DMSO 19 mg/mL (100.43 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Kynurenic acid (Quinurenic acid, Kynurenate), a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist; It proved to be an antagonist at NMDA, kainate and AMPA receptors.
Targets
α7 nicotinic acetylcholine receptor [1] glutamate receptors [2] NMDAR [4]
In vitro Kynurenic acid(KYNA) is neuroactive tryptophan metabolites formed along the kynurenine pathway. It is considered a non-competitive antagonist of glutamate receptors of NMDA type. KYNA, at low concentration, inhibits FGF-1 release in all cellular models and displays a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro[2].
In vivo Treatment with KYNA (30–100 mg per kg of body weight, intravenously) 4 h before the start of heat stress significantly (P<0.05) and dose-dependently decreases the survival time to new values of 152–356 min compared with normothermic rats. KYNA protects against hypotension but not hyperthermia during heatstroke. KYNA attenuates hypothalamic neuronal degeneration and apoptosis during heatstroke. Also spleen, kidney, liver, and lung apoptosis during heatstroke are decrease. KYNA up-regulates serum IL-10 levels but down-regulates serum TNF-α and ICAM-1 levels. KYNA treatment significantly prevents the occurrence of heat-induced multi-organ damage and inflammation without affecting the induced hyperthermia. Only high doses of KYNA proved to be neuroprotective in neonatal rats by reducing anoxia or hypoxia-ischemia-induced brain edema and in adult rats and gerbils given before ischemia induction. KYNA cannot cross the blood-brain barrier[3].

Protocol (from reference)

Animal Study:

[3]
  • Animal Models

    Adult male Sprague-Dawley rats

  • Dosages

    30-100 mg/kg

  • Administration

    i.v

Selleck's Kynurenic acid has been cited by 2 publications

Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands [ Pharmaceuticals (Basel), 2023, 16(5)692] PubMed: 37242475
Organ-differential responses to ethanol and kynurenic acid, a component of alcoholic beverages in gene transcription. [ Gene, 2020, 737:144434] PubMed: 32018015

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.